A Study of TH-SC01 in the Treatment of Radiation-induced Rectal Injury
Rectal Injury
About this trial
This is an interventional treatment trial for Rectal Injury
Eligibility Criteria
Inclusion Criteria: Fully understand and sign the informed consent form; Age ≥18 years and <80 years; Patients diagnosed with chronic radiation rectal injury after radiation therapy; Patients with LENT-SOMA scale score ≥1; Good physical condition (WHO functional status score 0-1). Exclusion Criteria: The patient had severe liver and kidney disease; Severe congestive heart failure or coronary heart disease; Patients have allergic constitutions or severe systemic immune diseases; The patient had active gastrointestinal hemorrhage or acute intestinal obstruction; Patients were pregnant or had other conditions that the investigators deemed unsuitable for inclusion in the study.
Sites / Locations
- Jinling Hospital, ChinaRecruiting
Arms of the Study
Arm 1
Experimental
TH-SC01 local injection treatment group
The trial was conducted in a non-randomized, single-center, single-arm, dose-escalation design. Three dose groups were preset, which were as follows: Low dose group: 3×10^7 live cells/person (6mL); Medium dose group: 6×10^7 live cells/person (12mL) ; High dose group: 1.2×10^8 live cells/person (24mL); Each subject should receive only one corresponding dose. Three subjects were enrolled in the low-dose group,If the safety of the subjects was good, the researchers evaluated the safety and efficacy data and entered the next dose group for treatment. The medium and high-dose groups were enrolled according to the "5+7" principle. For the first 3 dose groups, after safety evaluation by the investigators, the maximum dose could reach 2.4×10^8 live cells/person (48mL). If the MTD group is not identified by the highest dose group, it is up to the investigator to decide whether to continue with dose escalation.